Evidence map›Paper›PMID 32530102›Full record

Observational studyBritish journal of clinical pharmacology2021

Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis.

Suzanne Arends, Freke Wink, Joyce Veneberg, Reinhard Bos, Eric van Roon, Eveline van der Veer, Fiona Maas, Anneke Spoorenberg

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in British journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Suzanne ArendsRheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, RB, The Netherlands.ORCID 0000-0002-4422-7640
Freke WinkRheumatology, Medical Center Leeuwarden, Leeuwarden, BR, The Netherlands.
Joyce VenebergRheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, RB, The Netherlands.
Reinhard BosRheumatology, Medical Center Leeuwarden, Leeuwarden, BR, The Netherlands.
Eric van RoonClinical Pharmacy and Pharmacology, Medical Center Leeuwarden, Leeuwarden, BR, The Netherlands.
Eveline van der VeerLaboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, RB, The Netherlands.
Fiona MaasRheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, RB, The Netherlands.
Anneke SpoorenbergRheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, RB, The Netherlands.
University Medical Center Groningen · NLMedisch Centrum Leeuwarden · NLUniversity of Groningen · NL

Funding

PfizerPfizer pharmaceuticals
6 · The paper itself

Abstract

aimsTo evaluate whether 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements has an effect on lumbar spine and hip bone mineral density (BMD) in ankylosing spondylitis (AS) patients starting tumour necrosis factor-α inhibitors or receiving conventional treatment. Secondly, to explore the development of radiographic vertebral fractures.

methodsPatients from the Groningen Leeuwarden AS cohort receiving bisphosphonates based on clinical indication and available 2-year follow-up BMD measurements were included. BMD of lumbar spine (L1-L4) and hip (total proximal femur) were measured using dual-energy X-ray absorptiometry. Spinal radiographs (Th4-L4) were scored for vertebral fractures according to the Genant method.

resultsIn the 20 included patients (median 52 years, 14 males), lumbar spine and hip BMD Z-scores increased significantly; median from -1.5 (interquartile range [IQR] -2.2 to 0.4) to 0.1 (IQR -1.5 to 1.0); P < .001 and median from -1.0 (IQR -1.6 to -0.7) to -0.8 (IQR -1.2 to 0.0); P = .006 over 2 years, respectively. In patients also treated with tumour necrosis factor-α inhibitors (n = 11), lumbar spine and hip BMD increased significantly (median 2-year change +8.6% [IQR 2.4 to 19.6; P = .009] and +3.6% [IQR 0.7-9.0; P = .007]). In patients on conventional treatment (n = 9), lumbar spine BMD increased significantly (median 2-year change +3.6%; IQR 0.7 to 9.0; P = .011) and no improvement was seen in hip BMD (median -0.6%; IQR -3.1 to 5.1; P = .61). Overall, younger AS males with limited spinal radiographic damage showed most improvement in lumbar spine BMD. Four mild radiographic vertebral fractures developed in 3 patients and 1 fracture increased from mild to moderate over 2 years in postmenopausal women and middle-aged men.

conclusionThis explorative observational cohort study in AS showed that 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements significantly improves lumbar spine BMD. Mild radiographic vertebral fractures still occurred.

Indexed as

Spinal FracturesSpondylitis, AnkylosingAbsorptiometry, PhotonBone DensityDiphosphonatesFemaleHumansMaleMiddle AgedDiphosphonatesankylosing spondylitisbisphosphonatesbone mineral densitytumour necrosis factor-α inhibitorsvertebral fractures

Identifiers

PMID32530102
PMCPMC9328658
OpenAlexW3035533446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.